Arcturus Therapeutics Holdings Inc.
Close on Oct 19, 2026
- Market cap
- $296.17M
- P/E (TTM)
- –
- Dividend yield
- –
About Arcturus Therapeutics
Pharmaceutical Preparations, SIC 2834
Arcturus is a biotechnology company that develops messenger RNA medicines and vaccines targeting rare diseases and infectious conditions. The company utilizes proprietary lipid nanoparticle delivery and self-amplifying mRNA platforms to design its products. Its pipeline features KOSTAIVE, an approved self-amplifying mRNA vaccine for COVID-19, alongside therapeutic candidates in clinical evaluation for cystic fibrosis and ornithine transcarbamylase deficiency. Arcturus also advances vaccines against seasonal and pandemic influenza. The company collaborates with pharmaceutical partners, including CSL Seqirus and Meiji Seika Pharma, to commercialize vaccines, and targets patients with rare genetic respiratory and liver disorders.
Commercial distribution of the company's vaccine currently centers in Japan, with regulatory authorizations also established in the European Union and the United Kingdom. Its clinical development activities and clinical trials take place across several regions, including the United States, Europe, and Vietnam. The provided text does not mention the location of the company's headquarters.
Summary of the business section of Arcturus Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Arcturus Therapeutics Holdings Inc.
- Headquarters
- San Diego, CA
- Address
- 10285 Science Center Drive
- Phone
- (858) 900-2660
- Employees
- 111, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, San Diego, California
Stock & identifiers
- Ticker
- ARCT
- Exchange
- Nasdaq
- Shares outstanding
- 28M, Aug 4, 2026
- Public float
- $323.50M, Jun 30, 2025
- Filer category
- Accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-7 reverse, Nov 16, 2017
- SEC CIK
- 1768224
- CUSIP
- 03969T109
- ISIN
- US03969T1097
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joseph E. Payne | President and CEO, Director | 1,480,097 |
| Andy Sassine | Chief Financial Officer, Director | 221,764 |
| Dennis Mulroy | Chief Financial Officer | – |
| Pad Chivukula | Chief Scientific Officer & COO | 435,334 |
| Lance Kurata | Chief Legal Officer | – |
| Joseph Roberts | Controller | 2,201 |
| Jing L. Marantz | Director | 3,131 |
| Magda Marquet | Director | 28,073 |
| Peter C. Farrell | Director | 98,696 |
| Moncef Slaoui | Director | – |
| Edward W. Holmes | Director | 3,131 |
| John Markels | Director | 3,131 |
| James F. Barlow | Director | 13,131 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 111 employees, of which 106 were full-time and 5 were part-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 12, 2025 | Late filing | Notification of late filing |
| Apr 5, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 10, 2021 | Late filing | Notification of late filing |
| Mar 18, 2019 | Merger | Registration of securities for a merger or exchange offer (S-4) |